21 mai 2012

Development and manufacture of drug substances (chemical entities and biotechnological/biological entities) Q11

This new guidance is proposed for Active Pharmaceutical Ingredients (APIs) harmonising the scientific and technical principles relating to the description and justification of the development and manufacturing process (CTD sections S 2.2. - S 2.6) of Drug Substances including both chemical entities and biotechnological/biological entities.

Download file

Read more ...

39(3) In-Process Revision (May-June 2013)
OMS Statistiques Sanitaires Mondiales 2013
Eudralex Volume 10 : Clinical Trials - Chapter V Guidance documents applying to clinical trials - Questions & Answers Document, Version 11.0 (May 2013)
Proposal for revision of the supplementary guidelines on Good Manufacturing Practices: validation, appendix 7: non-sterile process validation
Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventin Cross-Contamination
EudraGMP Database now also comprises GDP Information
Revision of the EU GMP Guide : EU Commission Proposal for Chapter 6 - Quality Control
Importation of active substances for medicinal products for human use
HAS Description de la régulation de la promotion des produits de santé en France
CDER / CBER Guidance Formal Dispute Resolution: Appeals Above the Division Level